Perrigo gaps up after results, guidance, levels to watch The shares are up over 5.5% at time of writing, which is closer to the lows of the session so far. The company beat consensus expectations for its Q2 when it reported earnings of $1.36, 5 cents higher than estimated. Resistance is at $107.48. Support is at the session low at $105.05.
Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.